Cancer drug resistance: an evolving paradigm : Nature Reviews ... 24 Sep 2013 ... The CSC model has fundamental implications for cancer therapeutics and drug resistance. CSCs (or cancer cells with stem-cell-like properties) ...
Secrets of Lung Cancer Drug Resistance Revealed at UCSF | ucsf.edu People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return — it's a question of when. And for far too many, it happens far
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer | GRACE :: Lung Cancer Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect ... Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new d
Secrets of lung cancer drug resistance revealed -- ScienceDaily People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return -- it's a question of when. And for far too many, it happens far
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erloti 1. Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T ..
Identification of mutations causing lung cancer resistance leads to new treatment strategies Cancer September 17, 2014 Identification of mutations causing lung cancer resistance leads to new treatment strategies Two mutations that cause lung cancer resistance ... Although the targeted cancer treatment drug crizotinib is very effective in causing
Acquired resistance to TKIs in solid tumours: learning from lung cancer : Nature Reviews Clinical On The use of advanced molecular profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer (NSCLC), has revolutionized the treatment of this disease. However, acquir
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lu 1. J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH ...
Lung cancer - Wikipedia, the free encyclopedia Lung cancer, also known as carcinoma of the lung or pulmonary carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. If left untreated, this growth can spread beyond the lung by process of metastasis into ne
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer | GRACE :: Lung Cancer EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial. ... Dr. West, this is kind of an aside but also relevant to the ongoing research of these drugs. It sounds like it is possible for
